Patients with initially unresectable colorectal liver metastases benefit from certain induction therapies that increase surgical conversion potential.

• Bevacizumab plus triplet chemotherapy showed a 99% probability of improving R0-1 resection rates and progression-free survival.
• Bevacizumab plus doublet chemotherapy offers a more balanced benefit-risk profile, favoring safer patient outcomes.

Consider adjusting induction regimens based on genetic tumor profiles to optimize treatment effectiveness.

• Cetuximab plus doublet chemotherapy is the only regimen outperforming standard chemotherapy for wild-type KRAS/BRAF tumors in PFS.